Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?
about
Adoptive Cell Therapy in Multiple Myeloma.Leptin receptor antagonism of iNKT cell function: a novel strategy to combat multiple myeloma.Both mucosal-associated invariant and natural killer T-cell deficiency in multiple myeloma can be countered by PD-1 inhibitionCD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma.Immunological Approaches Towards Cancer and Inflammation: A Cross Talk.
P2860
Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?
description
2016 nî lūn-bûn
@nan
2016 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?
@ast
Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?
@en
Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?
@nl
type
label
Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?
@ast
Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?
@en
Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?
@nl
prefLabel
Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?
@ast
Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?
@en
Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?
@nl
P2093
P2860
P921
P356
P1433
P1476
Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?
@en
P2093
Dirk Elewaut
Karin Vanderkerken
Mérédis Favreau
P2860
P304
23128-23140
P356
10.18632/ONCOTARGET.7440
P407
P5008
P577
2016-04-26T00:00:00Z